Home › Astrocytoma
Astrocytoma clinical trials recruiting in the U.S.
47 studies for Astrocytoma are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX15 studies
- Boston, MA13 studies
- New York City, NY10 studies
- Chicago, IL9 studies
- Seattle, WA7 studies
- Philadelphia, PA7 studies
- Miami, FL7 studies
- Durham, NC7 studies
- San Francisco, CA6 studies
- Columbus, OH6 studies
- Aurora, CO6 studies
- Washington, DC5 studies
- Cincinnati, OH5 studies
- Salt Lake City, UT5 studies
- Los Angeles, CA4 studies
- St. Louis, MO4 studies
- Baldwin Park, CA4 studies
- Rochester, MN3 studies
- Queens, NY3 studies
- Edison, NJ3 studies
- San Antonio, TX3 studies
- Richmond, VA3 studies
- Nashville, TN3 studies
- Dallas, TX3 studies
- Detroit, MI3 studies
- Cleveland, OH3 studies
- Lexington, KY3 studies
- New Haven, CT3 studies
- Kansas City, KS3 studies
- Pittsburgh, PA3 studies
- Birmingham, AL3 studies
- Madison, WI3 studies
- Ann Arbor, MI3 studies
By state
- Alabama3 studies
- California10 studies
- Colorado7 studies
- Connecticut3 studies
- District of Columbia4 studies
- Florida9 studies
- Georgia3 studies
- Illinois9 studies
- Kansas3 studies
- Kentucky4 studies
- Massachusetts13 studies
- Michigan6 studies
- Minnesota5 studies
- Missouri4 studies
- New Jersey4 studies
- New York10 studies
- North Carolina8 studies
- Ohio9 studies
- Pennsylvania8 studies
- Tennessee4 studies
- Texas16 studies
- Utah5 studies
- Virginia5 studies
- Washington8 studies
- Wisconsin3 studies
Recently updated studies
Observational Connectomics in Adults Undergoing Resection of WHO II-IV Glioma
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07927595Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-Being
Recruiting
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07628647Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Nov 3, 2026 · NCT07215910GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07301268A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT05765812Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT07544992Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT06815029Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT06860594Implantable Microdevice In Primary Brain Tumors
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT04135807SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT05303519Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Oct 16, 2026 · NCT06344130Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Oct 9, 2026 · NCT07439172Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
RecruitingPhase 1/2
Ages 18 to 130 · All sexes · Updated Oct 5, 2026 · NCT05417594MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT03896568Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma
RecruitingPhase 2
Ages 18 to 98 · All sexes · Updated Sep 21, 2026 · NCT07831369A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Sep 14, 2026 · NCT05698524SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
RecruitingPhase 1/2
Ages 2 to 24 · All sexes · Updated Sep 11, 2026 · NCT04923126FearLess in NeuroOncology
Recruiting
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06989086Targeted Pediatric High-Grade Glioma Therapy
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RecruitingPhase 1
36 Months – 22 Years · All sexes · Updated Sep 4, 2026 · NCT03911388Serial MRI Scans During Radiation Therapy
Recruiting
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT04188535Study of Olutasidenib and Temozolomide in HGG
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT07733674Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT04623931From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.